|
|
|
| Advance of BET family and its inhibitors in tumor |
| ZHOU Xiao CHENG Zhixiang |
| Department of Pain Management, the Second Affiliated Hospital, Nanjing Medical University, Jiangsu Province, Nanjing 210011, China |
|
|
|
Abstract Bromodomain and extra terminal domain (BET) family is one of bromodomain proteins, which is up-regulated in various tumors and involved in tumor pathogenesis by regulating cell growth, proliferation and differentiation, apoptosis and necrosis. Several BET inhibitors have been developed and clinically tested, the antitumor efficacy of BET inhibitor alone or in combination with existing drugs has been identified in different tumors types, so it may become a new target for tumor treatment. This paper summarizes the current knowledge of BETs and its inhibitors in tumor.
|
|
|
|
|
|
[1] Ferri E，Petosa C，McKenna CE. Bromodomains：Structure，function and pharmacology of inhibition [J]. Biochem Pharmacol，2016，106：1-18.
[2] Cheung KL，Zhang F，Jaganathan A，et al. Distinct Roles of Brd2 and Brd4 in Potentiating the Transcriptional Program for Th17 Cell Differentiation [J]. Mol Cell，2017，65（6）：1068-1080.e5.
[3] Jung M，Gelato KA，Fernández-Montalván A，et al. Targeting BET bromodomains for cancer treatment [J]. Epigenomics，2015，7（3）：487-501.
[4] Huang Y，Nahar S，Nakagawa A，et al. Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment [J]. Clin Cancer Res，2016，22（16）：4259-4270.
[5] Sakurai N，Inamochi Y，Inoue T，et al. BRD4 regulates adiponectin gene induction by recruiting the P-TEFb complex to the transcribed region of the gene [J]. Sci Rep，2017，7（1）：11962.
[6] Konuma T，Yu D，Zhao C，et al. Structural Mechanism of the Oxygenase JMJD6 Recognition by the Extraterminal（ET）Domain of BRD4 [J]. Sci Rep，2017，7（1）：16272.
[7] Bourova-Flin E，Chuffart F，Rousseaux S，et al. The Role of Bromodomain Testis-Specific Factor，BRDT，in Cancer：A Biomarker and A Possible Therapeutic Target [J]. Cell J，2017，19（Suppl 1）：1-8.
[8] Stathis A，Bertoni F. BET Proteins as Targets for Anticancer Treatment [J]. Cancer Discov，2018，8（1）：24-36.
[9] Xu Y，Vakoc CR. Targeting Cancer Cells with BET Bromodomain Inhibitors [J]. Cold Spring Harb Perspect Med，2017，7（7）. Pii：a026674.
[10] Wang R，You J. Mechanistic analysis of the role of bromodomain-containing protein 4（BRD4）in BRD4-NUT oncoprotein-induced transcriptional activation [J]. J Biol Chem，2015，290（5）：2744-2758.
[11] Zee BM，Dibona AB，Alekseyenko AA，et al. The Oncoprotein BRD4-NUT Generates Aberrant Histone Modification Patterns [J]. PLoS One，2016，11（10）：e0163820.
[12] Saygin C，Carraway HE. Emerging therapies for acute myeloid leukemia [J]. J Hematol Oncol，2017，10（1）：93.
[13] Saenz DT，Fiskus W，Manshouri T，et al. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells [J]. Leukemia，2017，31（3）：678-687.
[14] Tontsch-Grunt U，Rudolph D，Waizenegger I，et al. Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo [J]. Cancer Lett，2018，421：112-120.
[15] Bui MH，Lin X，Albert DH，et al. Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies [J]. Cancer Res，2017，77（11）：2976-2989.
[16] Marcotte R，Sayad A，Brown KR，et al. Functional Genomic Landscape of Human Breast Cancer Drivers，Vulnerabilities，and Resistance [J]. Cell，2016，164（1/2）：293-309.
[17] Feng Q，Zhang Z，Shea MJ，et al. An epigenomic approach to therapy for tamoxifen-resistant breast cancer [J]. Cell Res，2014，24（7）：809-819.
[18] Andrieu GP，Denis GV. BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition [J]. Mol Cancer Res，2018，16（4）：580-586.
[19] Lenhart R，Kirov S，Desilva H，et al. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression [J]. Mol Cancer Ther，2015，14（10）：2167-2174.
[20] Liao YF，Wu YB，Long X，et al. High level of BRD4 promotes non-small cell lung cancer progression [J]. Oncotarget，2016，7（8）：9491-9500.
[21] Lam LT，Lin X，Faivre EJ，et al. Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors [J]. Mol Cancer Ther，2017，16（8）：1511-1520.
[22] Zhang D，Leal AS，Carapellucci S，et al. Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762 [J]. Cancer Prev Res（Phila），2018，11（3）：143-156.
[23] Wang J，Wang Y，Mei H，et al. The BET bromodomain inhibitor JQ1 radiosensitizes non-small cell lung cancer cells by upregulating p21 [J]. Cancer Lett，2017，391：141-151.
[24] Wyce A，Matteo JJ，Foley SW，et al. MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers [J]. Oncogenesis，2018，7（4）：35.
[25] Jin X，Yan Y，Wang D，et al. DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4 [J]. Mol Cell，2018，71（4）：592-605.e4.
[26] Berthon C，Raffoux E，Thomas X，et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia：a dose-escalation，phase 1 study [J]. Lancet Haematol，2016，3（4）：e186-195.
[27] Lewin J，Soria JC，Stathis A，et al. Phase Ib Trial With Birabresib，a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins，in Patients With Selected Advanced Solid Tumors [J]. J Clin Oncol，2018：JCO2018 782292. |
|
|
|
